Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.61 |
| ▸ | ERBB2 | P04626 | 10/20 | 0.61 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.51 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.51 |
| ▸ | GAK | O14976 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034347 | 0.94 | EGFR (0.59) | EGFRERBB2ERBB4ERBB3 | |
| SCHEMBL4034844 | 0.93 | EGFR (0.74) | EGFRERBB2 | |
| SCHEMBL4037940 | 0.91 | EGFR (0.63) | EGFRERBB2ERBB4ERBB3 | |
| Trifluoroacetic Acid SCHEMBL4033922 | 0.89 | EGFR (0.63) | EGFRERBB2ERBB4ERBB3GAK | |
| SCHEMBL4037278 | 0.88 | EGFR (0.67) | EGFRERBB2ERBB4ERBB3GAK | |
| SCHEMBL4033543 | 0.87 | EGFR (0.66) | EGFRERBB2ERBB4ERBB3GAK | |
| SCHEMBL4033032 | 0.86 | EGFR (0.65) | EGFRERBB2ERBB4ERBB3GAK | |
| SCHEMBL4031808 | 0.86 | EGFR (0.65) | EGFRERBB2 | |
| Trifluoroacetic Acid SCHEMBL4034350 | 0.82 | EGFR (0.61) | EGFRERBB2ERBB4ERBB3 | |
| Trifluoroacetic Acid SCHEMBL4034843 | 0.81 | EGFR (0.76) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444211-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | EGFR 4/4885ERBB2 1/4885ERBB4 5/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885ERBB4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.